Related references
Note: Only part of the references are listed.Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
Fabio P. S. Santos et al.
BLOOD (2010)
Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease
Hajime Akada et al.
BLOOD (2010)
Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells
Ann Mullally et al.
CANCER CELL (2010)
Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice
Shu Xing et al.
BLOOD (2008)
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice
Ralph Tiedt et al.
BLOOD (2008)
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera
Gerlinde Werning et al.
CANCER CELL (2008)
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)
Francesca Patriarca et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Evidence and expertise in the management of polycythemia vera and essential thrombocythemia
G. Finazzi et al.
LEUKEMIA (2008)
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders
Elizabeth O. Hexner et al.
BLOOD (2008)
Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
A. Tefferi et al.
LEUKEMIA (2008)
Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F
K. Shide et al.
LEUKEMIA (2008)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Characterization of murine JAK2V617F-positive myeloproliferative disease
Thomas G. P. Bumm et al.
CANCER RESEARCH (2006)
Lenalidomide therapy in myelofibrosis with myeloid metaplasia
Ayalew Tefferi et al.
BLOOD (2006)
Activating alleles of JAK3 in acute megakaryoblastic leukemia
Denise K. Walters et al.
CANCER CELL (2006)
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model
Gerlinde Wernig et al.
BLOOD (2006)
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders
H Quentmeier et al.
LEUKEMIA (2006)
Signals for stress erythropoiesis are integrated via an erythropoietin receptor-phosphotyrosine-343-Stat5 axis
MP Menon et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
JAK2(V617F) expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis
Catherine Lacout et al.
BLOOD (2006)
JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation - Cross-talk with IGF1 receptor
J Staerk et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
CN Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia
G Barosi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia
A Tefferi et al.
BLOOD (2001)
Medical progress: Myelofibrosis with myeloid metaplasia.
A Tefferi
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
